The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 42002529.
- Also identified by DOI 10.5694/mja2.70188 and PMC identifier 13092460.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Seasonal influenza causes significant morbidity and mortality in Australia. Despite long-standing recommendations for influenza vaccination and nationally funded programs for higher risk age or population groups, coverage remains suboptimal, especially among children. Introduction of the intranasal live attenuated influenza vaccine (LAIV) in 2026 offers an additional safe and effective needle-free vaccine option. Easier administration may improve access by making delivery by a range of health care providers possible. This perspective article outlines the evidence supporting the use of the LAIV and its potential to improve vaccination uptake among children in Australia.
Medical subject headings
- Influenza Vaccines
- Influenza, Human